Opportunistic infections and other risks with newer multiple sclerosis therapies.
about
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsRisks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisA randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).The occurrence and prevention of foodborne disease in vulnerable people.Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.Lymphopenia, Infectious Complications, and Outcome in Spontaneous Intracerebral Hemorrhage.Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.Human herpes virus-6 encephalitis causing severe anterograde amnesia associated with rituximab, azathioprine and prednisolone combination therapy for dermatomyositis.[Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment.Immune evasion and the evolution of molecular mimicry in parasites.Th1-mediated experimental autoimmune encephalomyelitis is CXCR3 independent.
P2860
Q26752859-6898CAC1-88CE-466E-B14F-7F979687E569Q33802186-17F82DAC-9479-4C2D-AA2C-C5D7D6550207Q34409297-D8AB295E-78B5-478C-8EA5-DA1BA9A613B3Q34409308-6DF2AA87-4D81-4B96-A235-4333176DA2CCQ35173590-D947DDFF-88B5-4694-9006-1579E22A52ECQ35758657-659832D6-D94B-48F6-B954-4E34CC04EA88Q36234246-0B6B1DEF-D413-4392-906D-F995D20B86F9Q36572168-B8C1591B-5439-4F6D-A8C2-A78A61F3E1A7Q37361949-9A266C88-DE91-48B3-B5C6-EF552951BD22Q37997089-BFABBBAA-A91E-485F-9639-5A41FA341602Q38261176-FF00383C-D2DF-4A6D-B39D-EAFA971A8C2EQ39048354-4A874E9F-7D44-4540-A7E6-77B8201CEBD3Q39672574-F4B1B462-DBA3-4A40-BC9A-9C209E5EBA60Q40044090-C1BF5272-CA00-4A42-B68D-37A2958A360FQ40324412-5C5B096B-4702-43E5-84FA-822312D07FABQ41102110-2C571AFC-785E-42F3-B98D-716E2FD67BD9Q41921804-4829C6D7-D064-432F-B79D-2DF6D8CC9150Q43849501-E4A19A1B-3028-4DEE-BA07-ED970FA536D2Q47968165-7BBCD39B-F88A-4B8A-A79F-23247479EBE6
P2860
Opportunistic infections and other risks with newer multiple sclerosis therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Opportunistic infections and other risks with newer multiple sclerosis therapies.
@en
Opportunistic infections and other risks with newer multiple sclerosis therapies.
@nl
type
label
Opportunistic infections and other risks with newer multiple sclerosis therapies.
@en
Opportunistic infections and other risks with newer multiple sclerosis therapies.
@nl
prefLabel
Opportunistic infections and other risks with newer multiple sclerosis therapies.
@en
Opportunistic infections and other risks with newer multiple sclerosis therapies.
@nl
P2860
P356
P1433
P1476
Opportunistic infections and other risks with newer multiple sclerosis therapies.
@en
P2093
Joseph R Berger
Sidney Houff
P2860
P304
P356
10.1002/ANA.21630
P577
2009-04-01T00:00:00Z